Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

A Psychedelic & Nutraceutical Opportunity: A Boost for the Brain and Your Portfolio

A psilocybin mushroom, also known as a magic mushroom, offers infinite medical and scientific potential…from cognitive flexibility to potentially addressing clinical depression and eating disorders. There’s a lot we still don’t kn...
Dave Jackson | September 18, 2020 |

A ‘Barrier’ to Better Health

(Click image to play podcast) The blood-brain barrier plays an essential role in protecting the brain from blood-borne disease. But is also one of medicine’s great paradoxes – a system designed to protect the most sensitive region of the body bu...
Dave Jackson | September 29, 2020 |

A New Frontier in Psychedelic Therapeutics

Cybin X Kernel "A New Frontier in Psychedelic Therapeutics" About the partnership: Cybin Corporation ( N.CYBN , Forum ) will leverage Kernel’s Flow to quantify brain activity during psychedelic experiences in re...
Featured Submission | January 11, 2021 |

Bioasis Technologies: A Very BIG Year in Review

It’s been a very busy, big and ambitious year for Bioasis Technologies Inc. ( TSX-V.BTI , OTC:BIOAF , Forum ) – a biopharmaceutical company focused on revolutionizing science by transporting therapeutic payloads across the blood-brain barrier and...
Dave Jackson | December 17, 2020 |

The Revolutionary Co. That’s Breaking Through the Blood Brain Barrier

(Click image to play video) Delivery of therapeutics across the blood-brain barrier (BBB) and into the brain has been the single greatest challenge to treating hundreds of common and rare neurological diseases, including brain cancers, neurodegenerative diseases...
Dave Jackson | December 1, 2020 |

Why is this Company combining Artificial Intelligence and Psychedelics to address Mental Afflictions

(Click image to play video) Did you know that in Canada, it is estimated that by the age of 40, half of the population will have, or will have had, a mental illness? The recent surge of interest in psychedelic drugs is due to their potential for more effective tr...
Dave Jackson | May 10, 2021 |

HAVN Life Sciences: Using psychedelics, specifically mushrooms, to improve mental health

Mental health, as we know, controls a large part of how we interact with the world around us. Our next guest knows this and is working to improve the mental health of those struggling by using psychedelics, specifically mushrooms. Psychedelics are not federally l...
Brieanna McCutcheon | November 4, 2022 |

Cassava Sciences' Shares Trade Up 20% on Updated Phase 2a Alzheimer's Data

Shares of Cassava Sciences traded 20% higher after the firm presented additional data from the Phase 2a study of its investigational drug candidate PTI-125 for Alzheimer's disease to the Clinical Trials on Alzheimer's Disease conference in San Diego, Calif. Neurodegen...
Streetwise Reports | December 9, 2019 |

A psychedelic renaissance

Fifty-three years after LSD was banned by the FDA, psychedelic drugs are making a comeback. Only instead of being the pills, mushrooms and acid tabs that helped college students to “turn on, tune in, drop out” Timothy Leary-style, today’...
Richard (Rick) Mills | December 3, 2019 |

Aethlon Medical CEO Jim Joyce Discusses the Forthcoming 'Concussion' Movie and CTE Research Being Co

Aethlon Medical CEO Jim Joyce Discusses the Forthcoming 'Concussion' Movie and CTE Research Being Conducted by Aethlon's Exosome Sciences Subsidiary Source: Gail Dutton of The Life Sciences Report (12/22/15) https://www.thelifesciencesreport.com/pub/na/aethlon-medical...
Gail Dutton | December 23, 2015 |
1 2 3 4 5 6 7 8 9 10 ...